- Home
- MMTX vs ACRV Comparison
MMTX vs ACRV Comparison
Compare MMTX & ACRV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MMTX | ACRV |
|---|---|---|
| Founded | 2025 | 2018 |
| Country | Taiwan | United States |
| Employees | 2 | N/A |
| Industry | Blank Checks | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 89.1M | 82.2M |
| IPO Year | N/A | 2022 |
Fundamental Metrics
Financial Performance| Metric | MMTX | ACRV |
|---|---|---|
| Price | $10.12 | $1.52 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $11.67 |
| AVG Volume (30 Days) | 9.1K | ★ 359.9K |
| Earning Date | 01-01-0001 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 15.13 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $568.17 |
| P/E Ratio | $139.74 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.89 | $1.15 |
| 52 Week High | $10.11 | $3.56 |
Technical Indicators
Market Signals| Indicator | MMTX | ACRV |
|---|---|---|
| Relative Strength Index (RSI) | 84.21 | 44.16 |
| Support Level | N/A | $1.46 |
| Resistance Level | N/A | $1.86 |
| Average True Range (ATR) | 0.00 | 0.08 |
| MACD | 0.00 | 0.01 |
| Stochastic Oscillator | 100.00 | 55.17 |
Price Performance
Historical ComparisonAbout MMTX Miluna Acquisition Corp Class A Ordinary Share
Miluna Acquisition Corp is a blank check company.
About ACRV Acrivon Therapeutics Inc.
Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1; ACR-2316 a selective, dual WEE1/PKMYT1 inhibitor; and ACR-6840, a development candidate targeting CDK11. It has one reportable segment focused on the research and development of precision oncology therapies.